Colorectal Cancer
Entity.
- Evidence
- 1,815 documents · 406 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 21 Oct 2026
- Measured
- 7% of mentions say something specific about it; the rest only name it
- As of
- 22 Oct 2026
Where this comes from
- Frontiers Precision Oncology · 2026-10-21 · Perineural invasion is associated with an aggressive phenotype and reduced in vitro capecitabine sensitivity in colorectal cancer (opens the source in a new tab)
- Crc-Digest · 2026-10-21 · FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer (opens the source in a new tab)
- Crc-Digest · 2026-10-21 · Anti-IL-1α Antibody Meets Primary Endpoint in Refractory Metastatic CRC (opens the source in a new tab)
- Crit Rev Oncol Hematol · 2026-10-20 · The evolution of immunotherapy resistance in mismatch repair-deficient colorectal cancer: A spatiotemporal perspective. (opens the source in a new tab)
- J Immunother Cancer · 2026-10-20 · Observation versus maintenance immunotherapy after PD-1-induced clinical complete response in dMMR/MSI-H colorectal cancer managed non-operatively: a multicenter co… (opens the source in a new tab)
- Adv Sci (Weinh) · 2026-10-20 · MZF1 Inhibits TGFβ-1/SMAD Signaling by Transcriptionally Activating SnoN to Augment Tumorigenic Potential in Colon Cancer. (opens the source in a new tab)
- J Gastrointest Cancer · 2026-10-20 · Later-line Treatment Selection in Metastatic Colorectal Cancer: Trifluridine/Tipiracil Plus Bevacizumab, Regorafenib, and Fruquintinib. (opens the source in a new tab)
- Medical Daily · 2026-10-20 · Jemperli Wins Accelerated FDA Approval for a Rectal Cancer Subtype as Most Trial Patients Avoided Surgery (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-20 · Inflammation is an essential trigger for POLE-driven ultramutated colorectal cancer (opens the source in a new tab)
- Gut · 2026-10-20 · Endoscopic resection after neoadjuvant therapy for advanced rectal cancer with near-complete response: a retrospective multicentre case series. (opens the source in a new tab)
- J Natl Cancer Inst · 2026-10-20 · Effects of private health insurance coverage gains on colorectal cancer outcomes: a modeling study. (opens the source in a new tab)
- Mol Biomed · 2026-10-20 · Curcumin analogue FLLL32 induces ferroptosis by targeting the STAT3-GPX4/SLC40A1 axis in colorectal cancer. (opens the source in a new tab)
What is claimed about it
- Corroborated: Reported by three or more sources that did not copy each other.
- FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer Corroborated · first reported 19 Oct 2026